Composition for protecting brain neurons
Patent Information
- Application Number
- MYPI2025003849
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-05
- Filing Date
- 2023-12-19
- Publication Date
- 2024-06-26
AI Technical Summary
Current methods fail to effectively protect brain nerve cells from age-related oxidative stress, which leads to cognitive decline and neurodegenerative diseases, despite the known antioxidant effects of carotenoids and docosahexaenoic acid.
A composition combining lutein and/or its fatty acid ester with docosahexaenoic acid in a specific weight ratio of 10 to 120, which synergistically protects brain nerve cells by reducing oxidative stress and promoting neuroprotection.
The composition significantly reduces LDH release levels, indicating enhanced protection of brain nerve cells and improved cognitive function, particularly when used within the specified ratio of lutein to docosahexaenoic acid.
Smart Images

Figure PI2025003849_DRAWING_001
Abstract
Description
Composition for protecting brain nerve cells
[0001] The present invention relates to a composition for protecting brain nerve cells, etc.
[0002] The brain is a metabolically active tissue that consumes oxygen actively and produces a large amount of reactive oxygen species. Reactive oxygen species increase in the brain with aging, and many studies have shown a correlation between increased oxidative stress and age-related cognitive decline. Therefore, it is important to appropriately control oxidative stress (Non-Patent Documents 1 and 2). Degeneration and necrosis of brain neurons caused by aging and oxidative stress can lead to diseases and disorders such as dementia, and declines in higher brain and cognitive functions. A highly safe method for protecting brain neurons is desired.
[0003] Carotenoids are antioxidants produced by plants, algae, bacteria, etc., and are found in large quantities in vegetables and fruits. They are known for their strong antioxidant properties (Non-Patent Documents 3 and 4). Sixteen types of carotenoids have been reported to exist in the human brain (Non-Patent Document 5). Among these, lutein and zeaxanthin, carotenoids abundant in vegetables such as Japanese mustard spinach (Komatsuna) (Non-Patent Document 6), are known to have neuroprotective effects due to their antioxidant properties in the central nervous system (Non-Patent Documents 7 and 8). Docosahexaenoic acid (DHA), a fatty acid component of oils and fats contained in fish oils from blue-skinned fish such as mackerel, saury, and sardines, is also known to have many physiological activities. Non-Patent Document 8 reports the neuroprotective effect of a composition containing lutein and DHA, with a lutein to DHA weight ratio of 0.72, but the effect is comparable to that of DHA alone. Patent Document 1 discloses an oral composition for improving brain function, which contains DHA, capsanthin, lutein, and zeaxanthin.
[0004] Patent No. 6375296
[0005] Ionescu-Tucker, A. & Cotman, C. W. Neurobiol. Aging 107, 86-95 (2021) Kandlur, A. et al. Front. Mol. Neurosci. 13, 41 (2020) Manochkumar, J. et al. Phytomedicine 91, 153676 (2021) Maoka, T. J. Nat. Med. 74, 1-16 (2020) Craft, N. E. et al. J. Nutr. Health Aging 8, 156-162 (2004) Aizawa, K. & Inakuma, T. Food Sci. Technol. Res. 13, 247-252 (2007) Singhrang, N. et al. J. Biomed. Pharmacother. 103, 582-587 (2018) Hu, Y. et al. J. Nutr. Sci. Vitaminol. (Tokyo). 67, 234-242 (2021)
[0006] Patent Document 1 does not clarify the protective effect of the oral composition on brain nerve cells.
[0007] An object of the present invention is to provide a composition for protecting brain nerve cells.
[0008] The present inventors have conducted extensive research to solve the above-mentioned problems and have discovered that by combining lutein and / or its fatty acid esters with docosahexaenoic acid compounds in a specific ratio range, brain nerve cells are protected more effectively (synergistically) than when lutein and / or its fatty acid esters or docosahexaenoic acid compounds are used alone, thereby completing the present invention.
[0009] The present invention relates to the following composition: [1] A composition for protecting brain neurons, comprising the following components (A) and (B): (A) lutein and / or a fatty acid ester thereof; and (B) a docosahexaenoic acid compound, wherein the weight ratio ((B) / (A)) of component (B) (converted to docosahexaenoic acid) to component (A) (converted to lutein) is 10 to 120. [2] The composition according to [1] above, wherein the docosahexaenoic acid compound is at least one selected from the group consisting of free docosahexaenoic acid, salts thereof, and compounds containing docosahexaenoic acid as a constituent fatty acid. [3] The composition according to [2] above, wherein the compound containing docosahexaenoic acid as a constituent fatty acid is selected from the group consisting of triglycerides whose constituent fatty acids are all or partly docosahexaenoic acid, diglycerides whose constituent fatty acids are all or partly docosahexaenoic acid, monoglycerides whose constituent fatty acids are all or partly docosahexaenoic acid, phospholipids whose constituent fatty acids are all or partly docosahexaenoic acid, glycolipids whose constituent fatty acids are all or partly docosahexaenoic acid, and alcohol esters of docosahexaenoic acid. [4] The composition according to any of [1] to [3] above, wherein component (B) is derived from seafood. [5] The composition according to any of [1] to [4] above, which is an oral composition. [6] The composition according to any of [1] to [5] above, which is a food or beverage. [7] The composition according to any one of [1] to [6] above, which is labeled with at least one function selected from the group consisting of "maintaining cognitive function," "maintaining memory function," "maintaining attention function," "suppressing brain neuronal damage," "protecting brain neurons," "protecting brain neurons," "reducing oxidative stress in the brain," "protecting the brain from oxidative stress," and "antioxidation of the brain." [8] The composition according to any one of [1] to [7] above, further comprising zeaxanthin and / or its fatty acid ester, an arachidonic acid compound, and an eicosapentaenoic acid compound. [9] The composition according to [8] above, which is used for improving or suppressing the decline of memory function.
[0010] According to the present invention, a composition for protecting brain nerve cells can be provided.
[0011] FIG. 1 is a graph showing the rate of change in LDH release level due to compositions containing lutein and DHA (Examples 1 to 4, Comparative Example 6) and the predicted values of the rate of change (Comparative Example 2 + Comparative Example 5, Comparative Example 3 + Comparative Example 5, Comparative Example 2 + Comparative Example 4, and Comparative Example 3 + Comparative Example 4).
[0012] The composition for protecting brain nerve cells of the present invention (hereinafter also referred to as "the composition of the present invention") contains the following components (A) and (B): (A) lutein and / or its fatty acid ester; (B) a docosahexaenoic acid compound, and the weight ratio ((B) / (A)) of component (B) (converted to docosahexaenoic acid) to component (A) (converted to lutein) is 10 to 120. The composition of the present invention contains lutein and / or its fatty acid ester and a docosahexaenoic acid compound as active ingredients.
[0013] (Component (A): Lutein and / or Fatty Acid Esters Thereof) The composition of the present invention contains lutein and / or its fatty acid esters. Lutein is a type of carotenoid. Lutein and / or its fatty acid esters are contained in plants and the like, and can be prepared, for example, by extraction from plants. Lutein fatty acid esters are contained in, for example, green and yellow vegetables such as spinach, kale, broccoli, pumpkin, carrots, and peppers; fruits such as oranges, peaches, papayas, prunes, mangoes, avocados, raspberries, and rosehips; and marigold petals. In the present invention, plant-derived materials rich in lutein and / or its fatty acid esters may be contained in the composition of the present invention, as long as the effects of the present invention are achieved. Commercially available lutein and / or its fatty acid esters can also be used.
[0014] The fatty acid ester of lutein is a fatty acid ester in which a fatty acid is bonded to one or two hydroxyl groups of lutein. Examples of the fatty acid in the fatty acid ester of lutein include fatty acids having 4 to 20 carbon atoms, and preferably fatty acids having 8 to 18 carbon atoms. The fatty acid ester of lutein contained in the composition may be one type or two or more types. Lutein is produced by hydrolysis of the fatty acid ester of lutein.
[0015] (Component (B): Docosahexaenoic Acid Compound) The composition of the present invention contains a docosahexaenoic acid compound. As the docosahexaenoic acid compound, docosahexaenoic acid (free DHA), its salts, and derivatives thereof can be used. As the derivative of docosahexaenoic acid, for example, a compound having a structure in which docosahexaenoic acid is bonded, and a compound that enables docosahexaenoic acid to be separated by hydrolysis can be used. As the compound that enables docosahexaenoic acid to be separated by hydrolysis, a compound that contains docosahexaenoic acid as a constituent fatty acid can be mentioned. The docosahexaenoic acid compound contained in the composition may be one type, or two or more types.
[0016] The docosahexaenoic acid compound used in the present invention is preferably selected from the group consisting of free docosahexaenoic acid, its salts, and compounds containing docosahexaenoic acid as a constituent fatty acid. Examples of salts of docosahexaenoic acid include calcium salts and sodium salts.
[0017] The compound containing docosahexaenoic acid as a constituent fatty acid is preferably a compound selected from the group consisting of triglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid, diglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid, monoglycerides in which the constituent fatty acid is docosahexaenoic acid, phospholipids in which some or all of the constituent fatty acids are docosahexaenoic acid, glycolipids in which some or all of the constituent fatty acids are docosahexaenoic acid, and alcohol esters of docosahexaenoic acid. Among these, as the docosahexaenoic acid compound, triglycerides, diglycerides, and phospholipids in which some or all of the constituent fatty acids are docosahexaenoic acid are more preferred, triglycerides and diglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid are even more preferred, and triglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid are particularly preferred.
[0018] The docosahexaenoic acid compound used in the present invention is not limited in any way by its form or production method. It may be a chemically synthesized product, a natural product, or a genetically modified organism (e.g., Escherichia coli, yeast, or plants). Examples of natural products include those derived from seafood, algae, fungi (e.g., Colwellia bacteria, Labyrinthulae), and plants (e.g., Marchantia polymorpha) capable of producing DHA. Of these, it is preferable that the docosahexaenoic acid compound be derived from seafood. Alternatively, docosahexaenoic acid compounds extracted and / or purified from raw materials such as natural products containing docosahexaenoic acid compounds may be used, or the raw materials may be used as is to incorporate the docosahexaenoic acid compound into a composition. Examples of raw materials containing docosahexaenoic acid compounds include edible oils and fats, such as those extracted from fish oil, meat, and dairy products. The fish oil containing docosahexaenoic acid compounds is preferably fish oil concentrated so that the content of docosahexaenoic acid compounds (converted to docosahexaenoic acid) is 5% by weight or more, preferably 10% by weight or more, more preferably 50% by weight or more. For example, docosahexaenoic acid compounds extracted and / or purified from fish oil containing docosahexaenoic acid compounds may be used, or the fish oil may be used as is. In one embodiment, the composition of the present invention contains fish oil, and the docosahexaenoic acid compounds may be a part of the fish oil.
[0019] In the composition of the present invention, the weight ratio ((B) / (A)) of (A) lutein and / or its fatty acid ester (as lutein) to (B) docosahexaenoic acid compound (as docosahexaenoic acid) is 10 to 120. Combining (A) lutein and / or its fatty acid ester with (B) docosahexaenoic acid compound at the above weight ratio provides a significantly superior effect in protecting brain neurons. This weight ratio is preferably 15 to 100, more preferably 20 to 80, and even more preferably 20 to 60. The term "lutein-equivalent amount" or similar expressions refers to the amount of lutein when component (A) is lutein, and refers to the value obtained by multiplying the number of moles of the ester by the molecular weight of lutein when component (A) is a fatty acid ester of lutein. The amount of lutein and / or its fatty acid ester can be measured by HPLC (high-performance liquid chromatography). The amount in terms of docosahexaenoic acid or similar expressions refers to the amount when component (B) is free DHA. When component (B) is not free DHA, it refers to the amount converted into free DHA after liberating DHA by saponification or enzyme treatment. The amount of free DHA can be measured by gas chromatography (GC). When two or more components (A) are used, the amount of component (A) is the total amount of these. When two or more components (B) are used, the amount of component (B) is the total amount of these.
[0020] As used herein, brain neurons are neurons that constitute brain tissue. Protection of brain neurons refers to the suppression of brain neuron damage or brain neuron death. The protective effect on brain neurons can be evaluated based on common knowledge in the technical field to which the present invention pertains, and the method for doing so is not particularly limited. For example, the protective effect on brain neurons can be evaluated by measuring the amount of LDH released outside of brain neurons.
[0021] The compositions of the present invention can be used to prevent or improve conditions or diseases that can be prevented or improved by protecting brain neurons. Examples of such conditions or diseases include cognitive decline, memory decline, attention decline, brain neuronal death, brain neuronal damage, and increased oxidative stress in the brain. In one embodiment, the compositions of the present invention can be used to prevent or improve such conditions or diseases. In one embodiment, the compositions of the present invention may be used in subjects in need of such prevention or improvement. As used herein, "preventing a condition or disease" includes preventing the onset of a condition or disease, delaying the onset of a condition or disease, reducing the incidence of a condition or disease, and reducing the risk of developing a condition or disease. "Ameliorating a condition or disease" includes recovering a subject from a condition or disease, alleviating the symptoms of a condition or disease, and delaying or preventing the progression of a condition or disease. "Recovery" includes at least partial recovery. The compositions of the present invention can be used for both therapeutic and non-therapeutic purposes. "Non-therapeutic" is a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis.
[0022] The composition of the present invention can be provided in the form of, for example, a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc., but is not limited thereto. The composition of the present invention may itself be a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc. for protecting brain neurons, or may be a formulation or material such as an additive used therein. The composition of the present invention can be provided in the form of an agent, for example, but is not limited to this form. The agent can also be provided as a composition as is, or as a composition containing the agent. The composition of the present invention can also be said to be an agent for protecting brain neurons. The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. According to the present invention, an oral composition having excellent brain neuronal protective activity can be provided. Oral compositions include food or drink, oral pharmaceutical products, and oral quasi-drugs, and preferably food or drink.
[0023] The composition of the present invention may contain any additives and any components other than component (A) and component (B), as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, and those that can generally be used in foods and beverages, pharmaceuticals, quasi-drugs, feeds, etc. can be used.
[0024] Examples of optional components include zeaxanthin and / or its fatty acid esters, arachidonic acid compounds, eicosapentaenoic acid compounds, etc. The composition of the present invention preferably further contains zeaxanthin and / or its fatty acid esters, arachidonic acid compounds, and eicosapentaenoic acid compounds. In one embodiment, the composition of the present invention may contain lutein and / or its fatty acid esters, docosahexaenoic acid compounds, zeaxanthin and / or its fatty acid esters, arachidonic acid compounds, and eicosapentaenoic acid compounds as active ingredients.
[0025] Zeaxanthin is a type of carotenoid. Zeaxanthin and / or its fatty acid esters are contained in vegetables such as paprika and spinach, chicken eggs, marigold petals, etc., and can be prepared, for example, by extraction from plants. The composition of the present invention may contain plant-derived materials rich in zeaxanthin and / or its fatty acid esters. Commercially available zeaxanthin and / or its fatty acid esters can also be used.
[0026] Zeaxanthin fatty acid esters are fatty acid esters in which a fatty acid is bound to one or two hydroxyl groups of zeaxanthin. Examples of fatty acids in zeaxanthin fatty acid esters include fatty acids having 4 to 20 carbon atoms, preferably fatty acids having 8 to 18 carbon atoms. The composition may contain one type of zeaxanthin fatty acid ester, or two or more types. Zeaxanthin is produced by hydrolysis of the zeaxanthin fatty acid ester.
[0027] Examples of arachidonic acid compounds that can be used include arachidonic acid (free arachidonic acid), its salts, and derivatives thereof. Examples of arachidonic acid derivatives that can be used include compounds having a structure in which arachidonic acid is bound, and compounds that allow arachidonic acid to be separated by hydrolysis. Examples of compounds that allow arachidonic acid to be separated by hydrolysis include compounds containing arachidonic acid as a constituent fatty acid. Arachidonic acid compounds may be used alone or in combination of two or more. The arachidonic acid compounds are preferably selected from the group consisting of free arachidonic acid, its salts, and compounds that include arachidonic acid as a constituent fatty acid. Examples of arachidonic acid salts include calcium salts and sodium salts. The compound containing arachidonic acid as a constituent fatty acid is preferably a compound selected from the group consisting of triglycerides in which some or all of the constituent fatty acids are arachidonic acid, diglycerides in which some or all of the constituent fatty acids are arachidonic acid, monoglycerides in which the constituent fatty acid is arachidonic acid, phospholipids in which some or all of the constituent fatty acids are arachidonic acid, glycolipids in which some or all of the constituent fatty acids are arachidonic acid, and alcohol esters of arachidonic acid. Among these, the arachidonic acid-related compounds are more preferably triglycerides, diglycerides, and phospholipids in which some or all of the constituent fatty acids are arachidonic acid, more preferably triglycerides and diglycerides in which some or all of the constituent fatty acids are arachidonic acid, and particularly preferably triglycerides in which some or all of the constituent fatty acids are arachidonic acid.
[0028] The arachidonic acid compound is not limited in any way by its form or production method, and may be a chemically synthesized product, or may be derived from a natural product or a genetically modified organism (such as Escherichia coli, yeast, or a plant). Examples of natural products include those derived from seafood, algae, microorganisms, and plants (such as liverwort) that are capable of producing ARA. Among these, it is preferable that the arachidonic acid compound be derived from a microorganism. Examples of microorganisms include those belonging to the genera Mortierella, Conidiobolus, Pythium, Phytophthora, Penicillium, Cladosporium, Mucor, Fusarium, Aspergillus, Rhodotorula, Entomophthora, Echinosporangium, and Saprolegnia. In addition, arachidonic acid compounds extracted and / or purified from raw materials such as natural products containing arachidonic acid compounds may be used, or the raw materials may be used as they are and the arachidonic acid compounds may be contained in the composition. Examples of raw materials containing arachidonic acid compounds include edible oils and fats such as oils and fats produced by microorganisms, and oils and fats extracted from eggs, meat, and seafood. There are no particular limitations on the method for producing arachidonic acid compounds using microorganisms, and known methods, such as the method described in JP 2016-172770 A, can be used.
[0029] Examples of eicosapentaenoic acid compounds that can be used include eicosapentaenoic acid (free eicosapentaenoic acid, hereinafter also referred to as EPA), its salts, and derivatives thereof. Eicosapentaenoic acid compounds may be used alone or in combination of two or more. Examples of eicosapentaenoic acid derivatives include compounds having a structure in which eicosapentaenoic acid is bound, and compounds that enable eicosapentaenoic acid to be separated by hydrolysis. Examples of compounds that enable eicosapentaenoic acid to be separated by hydrolysis include compounds containing eicosapentaenoic acid as a constituent fatty acid. Eicosapentaenoic acid compounds may be used alone or in combination of two or more. Preferably, the eicosapentaenoic acid compound is selected from the group consisting of free eicosapentaenoic acid, its salts, and compounds that include eicosapentaenoic acid as a constituent fatty acid. Examples of eicosapentaenoic acid salts include calcium salts and sodium salts. The compound containing eicosapentaenoic acid as a constituent fatty acid is preferably a compound selected from the group consisting of triglycerides in which some or all of the constituent fatty acids are eicosapentaenoic acid, diglycerides in which some or all of the constituent fatty acids are eicosapentaenoic acid, monoglycerides in which the constituent fatty acid is eicosapentaenoic acid, phospholipids in which some or all of the constituent fatty acids are eicosapentaenoic acid, glycolipids in which some or all of the constituent fatty acids are eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid.Among these, the eicosapentaenoic acid compound is more preferably a triglyceride, diglyceride, or phospholipid in which some or all of the constituent fatty acids are eicosapentaenoic acid, more preferably a triglyceride or diglyceride in which some or all of the constituent fatty acids are eicosapentaenoic acid, and particularly preferably a triglyceride in which some or all of the constituent fatty acids are eicosapentaenoic acid.
[0030] The eicosapentaenoic acid compound is not limited by its form or production method, and may be a chemically synthesized product, a product derived from natural products, or a product derived from a genetically modified organism (e.g., Escherichia coli, yeast, or plant). Examples of natural products include those derived from seafood, algae, fungi (e.g., Labyrinthula), and plants (e.g., Marchantia polymorpha) capable of producing EPA. Among these, it is preferable that the eicosapentaenoic acid compound be derived from seafood. Furthermore, eicosapentaenoic acid compounds extracted and / or purified from raw materials such as natural products containing eicosapentaenoic acid compounds may be used, or the raw materials may be used as they are to contain the eicosapentaenoic acid compound in a composition. Examples of raw materials containing eicosapentaenoic acid compounds include edible oils and fats, such as oils and fats extracted from fish oil, eggs, meat, dairy products, and algae. The fish oil containing eicosapentaenoic acid compounds is preferably fish oil concentrated so that the content of eicosapentaenoic acid compounds (equivalent to eicosapentaenoic acid) is 5% by weight or more, preferably 10% by weight or more, more preferably 20% by weight or more. For example, eicosapentaenoic acid compounds extracted and / or purified from fish oil containing eicosapentaenoic acid compounds may be used, or the fish oil may be used as is.
[0031] In one aspect of the present invention, a composition containing (A) lutein and / or a fatty acid ester thereof, (B) a docosahexaenoic acid compound, zeaxanthin and / or a fatty acid ester thereof, an arachidonic acid compound, and an eicosapentaenoic acid compound, wherein the weight ratio ((B) / (A)) of component (B) (docosahexaenoic acid equivalent) to component (A) (lutein equivalent) is 10 to 120, is preferably used for improving or suppressing decline in cognitive function. The cognitive function is preferably memory function. Cognitive function such as memory function can be evaluated, for example, by the Cognitrax test. Cognitrax is a cognitive function test designed for Japanese people based on CNS Vital Signs, developed by CNS Vital Signs, Inc., a U.S. company (Gualtieri C T. et al. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 21(7):623-643(2006)). The composition of the present invention can be used, for example, to improve overall memory ability assessed by the Cognitrax test.
[0032] When the composition of the present invention is used as a food or beverage, various foods and beverages can be prepared by blending components usable in foods and beverages (e.g., food ingredients, food additives used as needed, etc.) with component (A) and component (B). The foods and beverages are not particularly limited, and examples thereof include general foods and beverages, health foods, health drinks, functional foods, foods for specified health uses, health supplements, and foods and beverages for patients. The health foods, functional foods, foods for specified health uses, health supplements, and the like can be used in various dosage forms such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, and liquid diets.
[0033] When the composition of the present invention is used as a pharmaceutical or quasi-drug, various dosage forms can be prepared by blending component (A) and component (B) with pharmacologically acceptable carriers, additives, etc. The dosage form may be any dosage form suitable for administration. Examples of dosage forms for oral administration include oral solid preparations such as tablets, coated tablets, fine granules, granules, powders, pills, capsules, dry syrups, and chewable preparations; and oral liquid preparations such as oral liquids and syrups. Examples of dosage forms for parenteral administration include injections, drip infusions, ointments, lotions, patches, suppositories, nasal preparations, and pulmonary preparations (inhalants). The pharmaceutical may be a pharmaceutical for non-human animals. Examples of the administration (ingestion) form of the pharmaceutical or quasi-drug include oral and parenteral (transdermal, transmucosal, enteral, injection, etc.) administration forms. From the viewpoint of more fully achieving the effects of the present invention, the administration form of the pharmaceutical or quasi-drug is preferably oral. The carriers, additives, etc. may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc.
[0034] When the composition of the present invention is used as a feed, it can be prepared by blending components usable in feed with component (A) and component (B). Examples of the feed include livestock feed for cattle, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, guinea pigs, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.
[0035] When the composition of the present invention is used to prepare foods and beverages, pharmaceuticals, quasi-drugs, feeds, etc., the method for producing them is not particularly limited, and they can be produced by a general method using component (A) and component (B).
[0036] The contents of component (A) and component (B) in the composition of the present invention can be appropriately set depending on the form of the composition, etc. The total content of lutein and / or its fatty acid esters (lutein equivalent) in the composition of the present invention is, for example, preferably 0.01 wt % or more, more preferably 0.1 wt % or more, and preferably 9 wt % or less in the composition. In one embodiment, the total content of lutein and / or its fatty acid esters (lutein equivalent) in the composition is preferably 0.01 to 9 wt %, more preferably 0.1 to 9 wt %.
[0037] The total content of docosahexaenoic acid compounds in the composition of the present invention (converted to docosahexaenoic acid) is, for example, preferably 1 wt % or more, more preferably 10 wt % or more, and preferably 80 wt % or less. In one embodiment, the total content of docosahexaenoic acid compounds (converted to docosahexaenoic acid) in the composition is preferably 1 to 80 wt %, more preferably 10 to 80 wt %.
[0038] When the composition of the present invention contains zeaxanthin and / or its fatty acid esters, the total content (in zeaxanthin equivalent) in the composition is, for example, preferably 0.01 wt % or more, more preferably 0.02 wt % or more, and preferably 5 wt % or less, more preferably 2 wt % or less. In one embodiment, the total content of zeaxanthin and / or its fatty acid esters (in zeaxanthin equivalent) in the composition is preferably 0.01 to 5 wt %, more preferably 0.02 to 2 wt %.
[0039] When the composition of the present invention contains arachidonic acid compounds, the total content thereof (in terms of arachidonic acid) in the composition is, for example, preferably 2% by weight or more, more preferably 4% by weight or more, and preferably 40% by weight or less, more preferably 32% by weight or less. In one embodiment, the total content of arachidonic acid compounds (in terms of arachidonic acid) in the composition is preferably 2 to 40% by weight, more preferably 4 to 32% by weight. The content of arachidonic acid can be measured by gas chromatography (GC).
[0040] When the composition of the present invention contains eicosapentaenoic acid compounds, the total content thereof (eicosapentaenoic acid equivalent) in the composition is, for example, preferably 1 wt % or more, more preferably 3 wt % or more, and preferably 40 wt % or less, more preferably 30 wt % or less. In one embodiment, the total content of eicosapentaenoic acid compounds (eicosapentaenoic acid equivalent) in the composition is preferably 1 to 40 wt %, more preferably 3 to 30 wt %. The content of eicosapentaenoic acid can be measured by gas chromatography (GC).
[0041] The composition of the present invention can be ingested or administered in an appropriate manner depending on its form. Preferably, the composition of the present invention is orally administered orally ingested. The intake amount (also referred to as the dosage) of the composition of the present invention is not particularly limited, as long as it is an amount (effective amount) that provides a brain neuron protective effect, and can be appropriately determined depending on the dosage form, administration method, subject body weight, etc. For example, when the composition of the present invention is orally administered or ingested by a human (adult) subject, the total dosage of lutein and / or its fatty acid esters is preferably 0.5 mg or more, more preferably 1 mg or more, even more preferably 3 mg or more, and preferably 200 mg or less, more preferably 100 mg or less, and even more preferably 80 mg or less per 60 kg body weight per day, calculated as lutein. Furthermore, the total dosage of docosahexaenoic acid compounds is preferably 10 mg or more, more preferably 100 mg or more, and preferably 2,000 mg or less, more preferably 1,000 mg or less per 60 kg body weight per day, calculated as docosahexaenoic acid. In one embodiment, the total dosage of lutein and / or its fatty acid esters, in terms of lutein, is preferably 0.5 to 200 mg, more preferably 1 to 100 mg, and even more preferably 3 to 80 mg per 60 kg of body weight per day for a human (adult). The total dosage of docosahexaenoic acid compounds, in terms of docosahexaenoic acid, is preferably 10 to 2,000 mg, more preferably 100 to 2,000 mg, and even more preferably 100 to 1,000 mg per 60 kg of body weight per day for a human (adult). It is preferable to ingest or administer the above amounts once or more times a day, for example, once a day, or in divided doses (e.g., 2 to 3 times a day). In one embodiment, it is preferable to orally ingest or administer the above amounts of lutein and / or its fatty acid esters and docosahexaenoic acid compounds to a human. In one embodiment, the composition of the present invention can be used to cause or administer to a human (adult) the above-mentioned amounts of lutein and / or its fatty acid esters and docosahexaenoic acid compounds per 60 kg of body weight per day.The total dosage of lutein and / or its fatty acid esters refers to the total amount of lutein and / or its fatty acid esters when two or more types of lutein and / or its fatty acid esters are used, and the total dosage of docosahexaenoic acid compounds refers to the total amount of docosahexaenoic acid compounds when two or more types of docosahexaenoic acid compounds are used.
[0042] When the composition of the present invention contains zeaxanthin and / or its fatty acid esters, the total dose of zeaxanthin and / or its fatty acid esters, when orally administered or ingested to a human (adult), is preferably 0.1 mg or more, more preferably 0.5 mg or more, and preferably 50 mg or less, more preferably 30 mg or less, and even more preferably 20 mg or less, in terms of zeaxanthin, per 60 kg of body weight per day. In one embodiment, the total dose of zeaxanthin and / or its fatty acid esters, in terms of zeaxanthin, is preferably 0.1 to 50 mg, more preferably 0.1 to 30 mg, and even more preferably 0.5 to 20 mg, per 60 kg of body weight per day for a human (adult).
[0043] When the composition of the present invention contains arachidonic acid analogues, the total dose of the arachidonic acid analogues when orally administered or ingested to a human (adult) is preferably 10 mg or more, more preferably 20 mg or more, even more preferably 30 mg or more, and preferably 500 mg or less, more preferably 400 mg or less, and even more preferably 300 mg or less, in terms of arachidonic acid, per 60 kg of body weight per day. In one embodiment, the total dose of the arachidonic acid analogues is preferably 10 to 500 mg, more preferably 20 to 400 mg, and even more preferably 30 to 300 mg, in terms of arachidonic acid, per 60 kg of body weight per day for a human (adult).
[0044] When the composition of the present invention contains an eicosapentaenoic acid compound, the total dosage of the eicosapentaenoic acid compound when orally administered or ingested to a human (adult) is preferably 10 mg or more, more preferably 20 mg or more, even more preferably 30 mg or more, and preferably 500 mg or less, more preferably 400 mg or less, and even more preferably 300 mg or less per 60 kg body weight per day, in terms of eicosapentaenoic acid. In one embodiment, the total dosage of the eicosapentaenoic acid compound is preferably 10 to 500 mg, more preferably 20 to 400 mg, and even more preferably 30 to 300 mg per 60 kg body weight per day, in terms of eicosapentaenoic acid, for a human (adult).
[0045] The composition of the present invention is preferably one that is ingested or administered continuously. The above-mentioned effects are expected to be enhanced by the continuous ingestion or administration of lutein and / or its fatty acid ester and docosahexaenoic acid compound. In one embodiment, the composition of the present invention is preferably ingested or administered continuously for preferably 1 week or more, more preferably 4 weeks or more, even more preferably 8 weeks or more, and particularly preferably 12 weeks or more.
[0046] The subject of administration is preferably a human or a non-human mammal, more preferably a human. Furthermore, subjects requiring or desiring protection of brain neurons are preferred as subjects for administration of the composition of the present invention. Suitable subjects include, for example, subjects desiring prevention or amelioration of the above-mentioned conditions or diseases. In one aspect, the composition of the present invention can also be used in healthy subjects for the purpose of preventing or ameliorating conditions or diseases that can be expected to be prevented or ameliorated by protecting brain neurons.
[0047] In one embodiment, the subject of administration of the present invention is preferably elderly or middle-aged people. Generally, elderly people refer to people 65 years of age or older, and middle-aged people refer to people 45 years of age or older but younger than 65 years of age. For example, the subject of administration of the composition of the present invention is preferably people 45 years of age or older, and more preferably people 55 years of age or older but younger than 80 years of age. In one embodiment, the subject of administration of the composition of the present invention is more preferably a subject with cognitive decline.
[0048] The composition of the present invention may be labeled on its packaging, container, instruction manual, etc. with one or more of the following: intended use, type of active ingredient, the above-mentioned effects, and method of use (e.g., ingestion method, administration method). The composition of the present invention may be labeled with a claim that it has a protective effect on brain neurons or an effect based on such an effect. The composition of the present invention may be labeled with one or more of the following functions: "maintaining cognitive function," "maintaining memory function," "maintaining attention function," "suppressing brain neuronal damage," "protecting brain neurons," "protecting brain neurons," "reducing brain oxidative stress," "protecting the brain from oxidative stress," and "antioxidation of the brain." In one aspect of the present invention, the composition of the present invention is preferably a food or beverage labeled with the above-mentioned label. The above-mentioned label may also be a claim that the composition is used to obtain the above-mentioned function.
[0049] The present invention also encompasses the use of lutein and / or its fatty acid esters and a docosahexaenoic acid compound for producing a composition for protecting brain neurons, in which the weight ratio of the docosahexaenoic acid compound (converted to docosahexaenoic acid) to the lutein and / or its fatty acid esters (converted to lutein) is 10 to 120.
[0050] The present invention also encompasses the following method: A method for protecting brain nerve cells, comprising administering a composition containing the following components (A) and (B): (A) lutein and / or its fatty acid ester; and (B) a docosahexaenoic acid compound, in which the weight ratio ((B) / (A)) of component (A) (converted to lutein) to component (B) (converted to docosahexaenoic acid) is 10 to 120.
[0051] The present invention also encompasses the following use: Use of the following composition for protecting brain neurons. A composition containing the following components (A) and (B): (A) lutein and / or its fatty acid ester; (B) a docosahexaenoic acid compound, wherein the weight ratio ((B) / (A)) of component (B) (converted to docosahexaenoic acid) to component (A) (converted to lutein) is 10 to 120. The above method or use may be a therapeutic method or use, or a non-therapeutic method or use. By administering the above composition to a subject, a protective effect on brain neurons is obtained.
[0052] In the above uses and methods, preferred aspects of the lutein and / or its fatty acid esters and the docosahexaenoic acid compound, as well as the ratios thereof, are the same as those for the composition of the present invention described above. As for the lutein and / or its fatty acid esters and the docosahexaenoic acid compound, one type or two or more types may be used. In the above uses and methods, it is preferable to administer (ingest) the composition to a subject at least once a day, for example, once to several times a day (e.g., two to three times a day). In the above uses and methods, it is preferable to orally administer (ingest) the composition. The above uses are preferably used in humans or non-human mammals, more preferably in humans.
[0053] In the above-mentioned uses and methods, it is sufficient to use one or more of lutein and / or its fatty acid esters and one or more of docosahexaenoic acid compounds in amounts that achieve the desired effect (which can also be called effective amounts). The preferred dosages and administration targets of the lutein and / or its fatty acid esters and the docosahexaenoic acid compounds are the same as those for the composition of the present invention described above.
[0054] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes both the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper and lower limits may be any combination of ranges. All academic literature and patent documents described in this specification are incorporated herein by reference.
[0055] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.
[0056] Examples 1 to 4 and Comparative Examples 1 to 6: Whether the combination of DHA and lutein has a protective effect on brain neurons was investigated using human neuroblastoma SH-SY5Y cells. Solutions were prepared by dissolving DHA (Sigma-Aldrich) and lutein (EXTRASYNTHESE S.A.) in DMSO (Nacalai Tesque, Inc.). Human neuroblastoma SH-SY5Y (obtained from ECACC) was induced to differentiate using a previously reported method (Shipley, M.M. et al. J. Vis. Exp. 108, 53193 (2016); Pezzini, F. et al. Cell. Mol. Neurobiol. 37, 665-682 (2017); Gimenez-Cassina, A. et al. J. Neurosci. Res. 84, 755-767 (2006)) with some modifications. The differentiated cells had a neuron-like morphology. The media used for culture are shown in Table 2.
[0057] SH-SY5Y was induced to sleep using medium 1, and CO 2 Incubator (37°C, 5% CO 2 , ambient O 2 The cells were cultured in a 48-well plate (AGC Technoglass Co., Ltd.) under a humidified atmosphere. The day after seeding using Medium 1, the cells were replaced with Medium 2. The medium was replaced with fresh Medium 2 every 2 to 3 days. On the 7th day, the cells were replaced with Medium 3 (DMSO concentration: 0.1 wt%) supplemented with DMSO or the above-mentioned DHA DMSO solution and / or lutein DMSO solution at the concentrations shown in Table 1, and the cells were further cultured for 7 days. The medium was replaced with Medium 3 every 2 to 3 days. On the 14th day, the cells were replaced with Medium 4 supplemented with rotenone (Sigma-Aldrich) to a final concentration of 0.2 μM, and the cells were cultured for 48 hours.
[0058] After 48 hours, the culture supernatant was removed and centrifuged at 400 × g for 10 minutes, after which the supernatant was collected. After removing the culture supernatant, PBS (Nacalai Tesque) supplemented with 0.1% Triton X-100 (Nacalai Tesque) was added to the cells, and the cells were centrifuged at 2,000 × g for 15 minutes, after which the supernatant was collected. The amount of lactate dehydrogenase (LDH) contained in the collected culture supernatant and cell lysate was measured using a Cytotoxicity LDH Assay Kit (Fujifilm Corporation). LDH is an enzyme present in the cytoplasm that normally remains in the cytoplasm, but is released into the culture supernatant when the cell membrane is damaged. Therefore, the higher the amount of LDH in the culture supernatant, the greater the degree of cell damage. The absorbance at 490 nm was measured using a Synergy HT (Agilent Technologies), and the average value (N=3 or 6) of the LDH release level (the ratio of the amount of LDH in the culture supernatant to the total amount of LDH in the culture supernatant and cell lysate) was calculated. The average value of the LDH release level in Comparative Example 1 (using Medium 3 supplemented with DMSO) was set to 100%. The results are shown in Table 1. The LDH release level was expressed as a relative value (%) to the LDH release level in Comparative Example 1 (100%).
[0059]
[0060]
[0061] Table 1 shows the LDH release level values in each Example and Comparative Example, and the rate of change from Comparative Example 1 (the difference in LDH release level compared to Comparative Example 1). Also shown is the sum of the rate of change from Comparative Example 1 for the combinations of Comparative Examples corresponding to the combinations of DHA and lutein used in Examples 1 to 4. Figure 1 shows the rate of change in Examples 1 to 4 and Comparative Example 6. Also shown is the sum of the rate of change from Comparative Example 1 for the combinations of Comparative Examples corresponding to the combinations of DHA and lutein used in Examples 1 to 4. In Figure 1, "Comparative Example 2 + Comparative Example 5" is the sum of the rate of change from Comparative Example 1 in Comparative Example 2 and the rate of change from Comparative Example 1 in Comparative Example 5, "Comparative Example 3 + Comparative Example 5" is the sum of the rate of change from Comparative Example 1 in Comparative Example 3 and the rate of change from Comparative Example 1 in Comparative Example 5, "Comparative Example 2 + Comparative Example 4" is the sum of the rate of change from Comparative Example 1 in Comparative Example 2 and the rate of change from Comparative Example 1 in Comparative Example 4, and "Comparative Example 3 + Comparative Example 4" is the sum of the rate of change from Comparative Example 1 in Comparative Example 3 and the rate of change from Comparative Example 1 in Comparative Example 4. "Comparative Example 2 + Comparative Example 5," "Comparative Example 3 + Comparative Example 5," "Comparative Example 2 + Comparative Example 4," and "Comparative Example 3 + Comparative Example 4" refer to the rate of change in LDH release level when lutein and DHA are combined, predicted from the LDH release level when lutein alone (Comparative Example 2 or 3) and DHA alone (Comparative Example 4 or 5).
[0062] (Results) As shown in Table 1, in Comparative Examples 2 to 5, in which DHA or lutein was used alone, there was no significant change in LDH release level compared to Comparative Example 1, and almost no protective effect on brain neurons was observed. Furthermore, as shown in Table 1 and FIG. 1, in Comparative Example 6, in which DHA and lutein were combined but the weight ratio (DHA / lutein) was outside the range of 10 to 120, there was also no significant change in LDH release level compared to Comparative Example 1, and almost no protective effect on brain neurons was observed. In contrast, in Examples 1 to 4, in which DHA and lutein were used in combination so that the weight ratio was within the range of 10 to 120, the LDH release level was reduced by 5% or more compared to Comparative Example 1. Furthermore, the rate of change in LDH release level in Examples 1 to 4 was significantly lower than the value predicted from the LDH release level in the case of DHA alone or lutein alone (Comparative Example 2 + Comparative Example 5, Comparative Example 3 + Comparative Example 5, Comparative Example 2 + Comparative Example 4, and Comparative Example 3 + Comparative Example 4), confirming a synergistic reduction in LDH release level. That is, it was shown that by combining DHA and lutein so that the weight ratio falls within the range of 10 to 120, a synergistic protective effect on brain nerve cells can be obtained.
[0063] These results clearly demonstrate that combining lutein and / or its fatty acid ester with a docosahexaenoic acid compound in a specific ratio exhibits a synergistic effect in protecting brain nerve cells.
[0064] Example 5: The effect of a combination of arachidonic acid, DHA, EPA, lutein, and zeaxanthin on memory function in elderly people with cognitive decline was investigated. Memory function was tested using the aforementioned Cognitrax (provided by Health Solutions, Inc.).
[0065] (Subjects) Healthy men and women aged 55 to 79 who complained of memory loss were used as subjects. Before the start of the study, the subjects underwent a cognitive function test, MoCA-J (Japanese version of Montreal Cognitive Assessment).
[0066] (Evaluation Sample) Test foods (soft capsules) containing long-chain highly unsaturated fatty acids (arachidonic acid 120 mg, DHA 300 mg, and EPA 100 mg), lutein 10 mg, and zeaxanthin 2 mg per 6 capsules were prepared (weight ratio (DHA / lutein) 30). In addition, a food with the same appearance but not containing the above ingredients was prepared as a control food.
[0067] (Evaluation Method) Healthy elderly subjects complaining of forgetfulness were given six tablets of the test food or control food per day for 12 consecutive weeks. Comprehensive memory tests (verbal memory test and visual memory test) were conducted using Cognitrax before and after 12 weeks of intake to evaluate memory function. Of the subjects who completed the study, 58 subjects (34 in the test food group and 24 in the control food group) who showed signs of cognitive decline before intake (MoCA-J score less than 23 points) were analyzed. The change in Cognitrax comprehensive memory before and after 12 weeks of intake, as well as the change corrected for baseline values, are shown in Table 3.
[0068]
[0069] (Results) As shown in Table 3, in subjects with cognitive decline, the group that ingested the test food showed a significantly greater improvement in memory function than the group that ingested the control food. These results clearly demonstrate that combining lutein, zeaxanthin, arachidonic acid, DHA, and EPA in a specified ratio is effective for improving memory function in humans.
Claims
1. A composition for protecting brain nerve cells, comprising the following components (A) and (B): (A) lutein and / or its fatty acid ester; and (B) a docosahexaenoic acid compound, wherein the weight ratio ((B) / (A)) of component (A) (converted to lutein) to component (B) (converted to docosahexaenoic acid) is 10 to 120.
2. The composition according to claim 1, wherein the docosahexaenoic acid compound is at least one selected from the group consisting of free docosahexaenoic acid, its salts, and compounds containing docosahexaenoic acid as a constituent fatty acid.
3. The composition described in claim 2, wherein the compound containing docosahexaenoic acid as a constituent fatty acid is selected from the group consisting of triglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid, diglycerides in which some or all of the constituent fatty acids are docosahexaenoic acid, monoglycerides in which the constituent fatty acid is docosahexaenoic acid, phospholipids in which some or all of the constituent fatty acids are docosahexaenoic acid, glycolipids in which some or all of the constituent fatty acids are docosahexaenoic acid, and alcohol esters of docosahexaenoic acid.
4. The composition according to any one of claims 1 to 3, wherein component (B) is derived from seafood.
5. The composition according to any one of claims 1 to 3, which is an oral composition.
6. The composition according to any one of claims 1 to 3, which is a food or drink.
7. The composition according to any one of claims 1 to 3, which is labeled with at least one function selected from the group consisting of "maintaining cognitive function", "maintaining memory function", "maintaining attention function", "suppressing brain neuronal damage", "protecting brain neurons", "protecting brain neurons", "reducing oxidative stress in the brain", "protecting the brain from oxidative stress" and "antioxidation of the brain".
8. The composition according to any one of claims 1 to 3, further comprising zeaxanthin and / or its fatty acid ester, an arachidonic acid compound and an eicosapentaenoic acid compound.
9. The composition according to claim 8, which is used for improving or preventing the decline of memory function.
